An interventional study of Combined Exercise Program + A specific nutritional plan for individuals with IBS and Aerobic Exercise + A specific nutritional plan for individuals with IBS in Fibromyalgia and Irritable Bowel Syndrome, sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis. Recruiting at 1 site in Italy. Open to female participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Fibromyalgia with a site in Italy — 16 open to participants now, 17 under way, none of them phase 3. Fibromyalgia · Italy.
Among the 41 studies in Fibromyalgia with a site in Italy, this one is the 23rd largest by planned enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2025, is one of 21 with no phase, reaches primary completion later than 16 of the 16 other live ones, and was the 29th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →16 of the 41 studies in Fibromyalgia with a site in Italy are open now. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 9–25
Italian Association for the Research and the Scientific Update · Sites in Italy
Ages 35–64 · Women only
IRCCS San Raffaele Roma · Sites in Italy
Ages 18–70
University of Roma La Sapienza · Sites in Italy
Ages 18–70 · Women only
Universita degli Studi di Genova · Sites in Italy
Ages 18–65 · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 30 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 80 across the 31 interventional studies, 69 across the 10 observational. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 41 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis is the lead sponsor of 55 studies on the registry; 19 are open to participants now.
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
8 of the studies in Fibromyalgia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06135753University of FlorencePsychosomatic Intervention in Fibromyalgia. | 2026-12-30 |
| NCT07641374Italian Association for the Research and the Scientific UpdateAuricular Acupuncture for Autonomic Balance and Pain in Fibromyalgia | 2026-12-31 |
| NCT07865403IRCCS San Raffaele RomaPsychologically Informed Telerehabilitation for Fibromyalgia | 2026-12-31 |
| NCT07785362Istituto Giannina GasliniNeuro-modulation of Central Pain Pathways in Non Inflammatory Musculoskeletal Pain Syndrome | 2027-03 |
| NCT07682090University of Roma La SapienzaTranscutaneous Vagus Nerve Stimulation for Pain and Autonomic Dysfunction in Fibromyalgia (RESET-FMS) | 2027-05-25 |
Add all 8 to your calendar (.ics) → With an account.
Among the 41 studies in Fibromyalgia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fibromyalgia (FM) is a chronic disorder marked by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties. Patients often experience hyperalgesia, allodynia, and muscle weakness. Central sensitization plays a key role, making the nervous system more responsive to pain. Though muscles are mainly affected, joint pain, stiffness, and reduced mobility are also common. Chronic pain and poor posture can worsen musculoskeletal health. FM is not mainly inflammatory, but pain and stress may affect bone health. Sleep disorders, like non-restorative sleep and apnea, are frequent and worsen fatigue. Neurotransmitter imbalances (e.g., serotonin, dopamine) affect pain and muscle function.
The American College of Rheumatology defines FM by widespread bilateral pain lasting at least three months. FM mainly affects women, with a prevalence of 0.2-6.6%, often starting between the ages of 30 and 35. Besides physical symptoms, many patients suffer from anxiety, depression, and mood disorders, affecting their quality of life.
Gastrointestinal issues, especially irritable bowel syndrome (IBS), are also frequent in FM patients. Both conditions share mechanisms such as pain hypersensitivity, altered autonomic regulation, gut-brain axis disruption, and immune dysfunction. Low-grade inflammation and intestinal permeability may contribute to chronic symptoms.
FM treatment includes anticonvulsants, antidepressants, and painkillers. IBS is managed with diet changes and medications like antispasmodics. Due to limited drug effectiveness, multidisciplinary approaches are gaining attention. Physical exercise is a proven non-drug strategy that improves pain, fatigue, and mental health in FM and IBS. Still, adherence is low due to fear of pain, fatigue, and low motivation.
Exercise, especially aerobic activity, benefits IBS patients by improving gut symptoms and reducing inflammation. It may also strengthen the gut barrier in both conditions. While optimal programs need more study, exercise is a promising therapy. Major health bodies recommend aerobic, resistance, and flexibility training for FM and aerobic exercise for IBS.
Patient Recruitment: The study is designed as a randomized crossover trial. Patients will be recruited from the "Rheumatology," "Pain Therapy," and "Celiac Disease and Functional Disorders" adult (30-65 years) outpatient clinics at the IRCCS "S. de Bellis" in Castellana Grotte (BA). Recruitment will take place following the confirmation of a diagnosis of irritable bowel syndrome (IBS) concomitant with fibromyalgia (FM).
Information regarding the participant's health status will be gathered through a comprehensive visit, encompassing an interview covering lifestyle, medical history, and a physical examination. Additionally, metabolic parameters, including blood sugar, HbA1c, lipid profile, and body weight, must fall within the normal range of values. Before providing written consent, all participants will receive verbal and written details of the study. The recruitment and evaluation of patients will be structured into the following phases:
V0. The patients will receive information about the study, sign an informed consent form, and complete a clinical history form. They will also maintain a daily symptom diary for 14 days. Furthermore, after confirming the inclusion criteria, participants will receive an accelerometer for 7 days to monitor their physical activity levels and sleep quality.
V1. Subjects will undergo blood sampling, urine, and stool sample collection, completion of questionnaires on gastrointestinal (GI) symptoms, fibromyalgia (FM), psychology, quality of life (QoL), and physical activity, as well as anthropometric measurements and bioimpedance analysis. Before the physical exercise intervention, field tests for physical fitness will be conducted, including handgrip strength tests, walking tests, and flexibility assessments. After obtaining certification of physical fitness for non-competitive sports activities, patients will be instructed to participate in a specific exercise program under the supervision of exercise specialists.
V2. Patients will repeat the GI, FM, psychology, QoL, and physical activity questionnaires. They will undergo the same functional tests and report adverse events. Blood and biological samples will be collected, and accelerometers will be worn for 7 days to assess changes in physical activity and sleep quality.
Washout Period. The washout period will last 4 weeks, during which recruited subjects will be returned as closely as possible to their baseline conditions. After these 60 days, subjects will be recalled, undergo the same evaluations, and be invited to participate in various physical exercise programs.
V3. During this visit, all evaluations from V1 will be repeated. Patients will also be asked to wear the accelerometer for seven days.
V4. During this visit, all evaluations from V2 will be repeated. All examinations will take place at the IRCCS "S. de Bellis," while motor tests and training sessions will be conducted at a gym affiliated with the institute.
Evaluation of FM Symptoms: To assess FM symptoms, a series of validated questionnaires, some specific to FM and others more general (e.g., the Fibromyalgia Impact Questionnaire, modified version (FIQ-R), Digital Tender Point examination, Brief Pain Inventory (BPI), and Pittsburgh Sleep Quality Index (PSQI) ), are utilized.
Evaluation of GI Symptoms: A patient's clinical history form is completed before assessing GI symptoms. Subsequently, two questionnaires are administered: the IBS-SSS, specific to IBS symptoms.
Psychological Assessment: The psychological profile is assessed using validated questionnaires. Initially, a history form identifies prior psychopathological disorders or family history. Additionally, first and second-level stress factors linked to symptoms are pinpointed. At baseline and day 120, participants complete pre- and post-administered psychological questionnaires covering various aspects, including the Symptom Checklist (SCL)-90-R, Perceived Stress Scale (PSS), World Health Organization Quality of Life-Brief (WHOQOL-Brief), Delaying Gratification Inventory (DGI), Rotter's Locus of Control Scale, Subjective Happiness Scale (SHS), Attachment Style Questionnaire (ASQ), and Psychological Well-Being Scales (PWBS).
Anthropometric and Bioimpedance Assessment: The subjects' physical characteristics (body weight, height, and circumferences) are assessed through direct measurement. Bioimpedance measurement involves a non-invasive, rapid, and quickly executed examination, ideal for measuring nutritional status (lean mass, fat mass, cellular and muscle mass), hydration status (water retention, swelling, hyperhydration, inflammation), basal metabolism, and "ideal weight".
Evaluation of Intestinal Permeability (IP): IP will be evaluated at baseline (day 0) and day 120. This involves administering a mixture of 40 g sucrose, 10 g lactulose, 5 g mannitol, and 1 g sucralose and measuring their gastrointestinal (GI) absorption through urinary excretion of these sugars. Urine will be collected over the next 5 hours in containers with added chlorhexidine (500 µL) as a preservative. The different sugars in the urine will be determined using high-pressure liquid chromatography (HPLC) and subsequent pulsed amperometric detection. Results will be expressed as a percentage of the excreted sugars in urine relative to the administered amount.
Barrier Peptide Assay: Zonulin, intestinal fatty acid binding protein (I-FABP), diamine oxidase (DAO), and D-lactate assays will be conducted at baseline (day 0) and day 120 using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) methods.
Indole and Skatole Assay: Indole will be assayed using a colorimetric analytical method, while skatole will be assessed using a refined chromatographic method with fluorimetric detection. Both assays will be conducted on a urine sample. This investigation will be conducted at baseline and day 120.
Biochemical analyses: blood levels of interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, and peptides involved in the regulation of GI motility (somatostatin, motilin, serotonin, somatostatin, motilin, serotonin, etc.)
Physical Activity Assessment: Physical activity levels will be measured using the International Physical Activity Questionnaire (IPAQ short-form) and accelerometer (ActiGraph GT9X Link), which will monitor physical activity and sleep quality. Additionally, participants will complete the Tampa Scale of Kinesiophobia (TSK) to assess their fear of movement.
Field tests will be conducted to evaluate physical fitness, including the 2 km walk test, Six Minutes Walking Test, Hand Grip Test, Sit and Reach Test, 30'' Sit to Stand test, Step Test, and Single Leg Stance (SLS). During the tests, symptoms, pain severity, fatigue, and exercise experience will be monitored in patients with fibromyalgia. Participants will be informed about the differences between exercise-induced soreness and pain/fatigue associated with fibromyalgia.
Treatments
Subjects will be randomized into two different intervention groups:
Treatment 1: A specific nutritional plan for individuals with IBS combined with a combined exercise program (CE).
Treatment 2: A specific nutritional plan for individuals with IBS combined with an aerobic exercise program (AE).
Intervention Protocol Based on existing literature, two interventions have been selected to identify the optimal exercise protocol for managing FM and IBS. The American College of Sports Medicine (ACSM) recommends combined exercise for FM, while aerobic exercise is effective for IBS. This study compares the two protocols to determine which is more suitable for individuals with both conditions, aiming to identify the most effective therapeutic approach.
Combined Exercise (CE) Frequency: 3 times per week for 4 months, on non-consecutive days. Intensity: Monitored with a heart rate monitor and personalized using Tanaka's formula. Additionally, the TALK TEST (a standardized, validated tool based on the subject's ability to maintain a conversation during exercise) and the Borg Scale will be used to measure exertion.
Aerobic Activity: 60-75% of max heart rate. Resistance: 6/7 on the Borg Scale. Flexibility: Range of motion (ROM) without pain. Type: Moderate aerobic exercise combined with resistance and flexibility exercises.
Aerobic Activity: Low-impact, non-weight-bearing exercises to minimize exercise-induced pain.
Resistance Activity: Circuit training with small equipment (resistance bands, dumbbells, ankle or wrist weights).
Flexibility Exercises: Stretching with and without bands. Duration: 60-minute sessions, including warm-up, aerobic, strength, and flexibility exercises, and cool-down, twice a week.
One specific session per week will focus on flexibility exercises. Joint mobility and flexibility exercises will be performed dynamically and statically after 20 minutes of aerobic exercise on machines.
Aerobic Exercise (AE) Frequency: 3 times per week for 4 months, on non-consecutive days. Intensity: Monitored with heart rate monitor, Tanaka's formula, TALK TEST, and Borg Scale. Aerobic activity at 60-75% of max heart rate.
Type: Low-impact, non-weight-bearing aerobic exercise. Duration: 60-minute sessions, including warm-up, aerobic activity, small circuits, and cool-down.
Both intervention protocols will be performed in small groups under the supervision of graduates in preventive and adapted exercise science. The exercise volume will be adjusted accordingly if symptoms worsen during group activities. Intensity or duration will be reduced before frequency to maintain regular activity.
Primary Endpoint: Perceived physical function will be assessed using the total score of the FIQ-R (higher scores indicate poorer functioning). The expected outcome is a 20% improvement in the total FIQ-R and IBS-SSS scores at the end of the intervention.
Secondary Endpoints: The effects of physical exercise on physical efficacy, dysbiosis, systemic inflammation, microbiota, and psychological profile will also be investigated.
Statistical Analysis:
Data will be presented as mean (SD) or median and 5th and 95th percentiles, depending on whether the variables are continuous or categorical. All comparisons will be made using non-parametric tests to avoid assuming a normal data distribution. Proportions related to dichotomous variables will be compared using the Chi-square test. P-values \<0.05 (two-tailed) will be considered statistically significant. All patients receiving physical activity instructions will be included in the statistical analysis for data comparison at the end of the treatment period, with dropouts categorized as non-responders (Intention To Treat analysis). The comparison of post-intervention data versus baseline will be conducted only for those who completed the intervention (per-protocol analysis). All statistical analyses will be performed using SigmaSTAT (Systat Software, Inc., San Jose, CA, USA) and GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). Questionnaire data will be entered into a database by a person not involved in the study.
Study Power Calculation:
The sample size is calculated to detect a 39% improvement in the total IBS-SSS score before and after the intervention. Considering a standard deviation of 30, a power of 0.80, and a significance level of 0.05, a minimum of 11 patients per group must be recruited. With a 27% dropout rate, each group will comprise 15 patients (total = 30).
The criteria were revised on the registry on Nov 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Fibromyalgia and IBS
Behavioral: Combined Exercise Program + A specific nutritional plan for individuals with IBS · Behavioral: Aerobic Exercise + A specific nutritional plan for individuals with IBS
Patients with Fibromyalgia and IBS
Behavioral: Combined Exercise Program + A specific nutritional plan for individuals with IBS · Behavioral: Aerobic Exercise + A specific nutritional plan for individuals with IBS
60-minute sessions three times per week for 4 months, incorporating moderate aerobic, resistance, and flexibility exercises
60-minute sessions, three times a week for 4 months, with low-impact, non-weight-bearing aerobic activities at 60-75% of max heart rate.
Fibromyalgia symptom assesment
To evaluate the effectiveness of an exercise intervention on IBS symptoms as measured by a change in the Fibromyalgia Impact Questionnaire, modified version (FIQ-R) scores from baseline. The FIQ serves as a tool for assessing and evaluating the condition of patients with fibromyalgia (FM) and tracking their progress and outcomes. Specifically designed to gauge the aspects of health status most impacted by FM, the FIQ comprises ten items. The initial item consists of 11 questions about physical functioning, each rated on a 4-point Likert-type scale. The subsequent items (2 and 3) prompt patients to indicate the number of days they felt well and the days they were unable to engage in work or housework due to FM symptoms. Items 4 through 10 feature horizontal linear scales with ten increments, allowing patients to rate work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety, and depression.
Time frame: At baseline and day 120
IBS symptoms assessment
To evaluate the effectiveness of an exercise intervention on IBS symptoms as measured by a change in the IBS-Symptom Severity Scale (IBS-SSS) questionnaire score from baseline. The IBS-SSS is a validated questionnaire for gastrointestinal symptoms and provides a global measure of symptom severity by assessing five items ("severity of abdominal pain", "frequency of abdominal pain", "severity of abdominal distension", "dissatisfaction with bowel habits", "impact of symptoms on quality of life") on a visual analog scale. The values of the five items are added together to give a total score between 0 and 500. Cases are then classified as 'mild' (75 to 175), 'moderate' (175 to 300) and 'severe' (\>300).
Time frame: At baseline and day 120
Physical Fitness assessment
Field tests to assess participants' physical fitness include the 2 km Walk Test, which evaluates cardiovascular fitness by recording heart rate and walking time before and after the test. The Six-Minute Walk Test measures aerobic fitness and functional capacity, requiring participants to walk as far as possible in 6 minutes, with heart rate monitored and exertion assessed using the Borg Scale. The Hand Grip Test assesses maximum hand and forearm strength using a dynamometer, with three tests per hand and the average recorded. The Sit and Reach Test measures flexibility in the back and legs, recording the best of two attempts. The 30-second Sit to Stand Test evaluates lower limb strength and endurance by counting the number of complete sit-to-stand movements in 30 seconds without using arms for support. The Step Test assesses cardiovascular endurance and lower limb function by having participants repeatedly step onto a standard-height step for 3 minutes, with recovery heart rate record
Time frame: Al Baseline and day 120
Psychological Assessment:
The Symptom Checklist (SCL)-90-R questionnaire will evaluate the psychological profile The Symptom Checklist-90-Revised (SCL-90-R) is a widely employed self-report questionnaire in clinical and research settings. It aims to evaluate diverse psychological symptoms and distress in individuals. Comprising 90 items, the SCL-90-R addresses dimensions of psychological well-being and psychopathology, including somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. Respondents use a Likert scale ranging from 0 (not at all) to 4 (extremely) to rate the extent of their experience with each symptom over a specified timeframe, typically the past week. This questionnaire offers a comprehensive profile of an individual's psychological symptoms, aiding in identifying areas of distress or dysfunction.
Time frame: At baseline and day 120
Evaluation of Barrier Peptide Integrity
Zonulin, I-FABP, DAO, and D-lactate assays will be performed using commercially available ELISA assays for each peptide.
Time frame: At baseline and day 120
Intestinal microbiota analysis
Any differences in the intestinal microbial population in the different disease patterns considered will be evaluated using appropriate genetic and molecular investigations (Illumina/Solexa Genetic Analyzer HiSeq) on the patient's stool samples.
Time frame: At baseline and day 120
Evaluation of Intestinal dysbiosis
The intestinal dysbiosis will be evaluated by assaying Indole using a colorimetric analytical method as a marker of fermentative dysbiosis, Skatole, a marker of putrefactive dysbiosis, will be assessed using a refined chromatographic method with fluorimetric detection. Both assays will be conducted on a urine sample.
Time frame: At baseline and day 120
Started Apr 2025 (actual). Primary completion is estimated for Sep 2028, 41 months after the start.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 41 months is above that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis